Chimeric Antigen Receptor (CAR) T Cells for the Treatment of a Kidney Transplant Patient with Post-transplant Lymphoproliferative Disorder (PTLD)

Investigators showed that even with the background of prolonged immunosuppression for solid organ transplant, it is possible to generate autologous CAR-T products capable of expansion and persistence in vivo, without evidence of excess T cell exhaustion.